Processing

Please wait...

Settings

Settings

Goto Application

1. WO2019186344 - ANTI-CANCER AND DISINTEGRIN SCORPION VENOMS

Publication Number WO/2019/186344
Publication Date 03.10.2019
International Application No. PCT/IB2019/052358
International Filing Date 22.03.2019
IPC
C07K 7/08 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
7Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
04Linear peptides containing only normal peptide links
08having 12 to 20 amino acids
CPC
C07K 7/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
7Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
04Linear peptides containing only normal peptide links
08having 12 to 20 amino acids
Applicants
  • INSTITUT PASTEUR DE TUNIS [TN]/[TN]
Inventors
  • KHARRAT, Riadh
  • KHAMESSI, Oussema
Priority Data
62/649,15128.03.2018US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) ANTI-CANCER AND DISINTEGRIN SCORPION VENOMS
(FR) AGENT ANTICANCÉREUX ET DISINTÉGRINE DE VENINS DE SCORPION
Abstract
(EN) The invention is related to novel scorpion venoms and methods of using the same in various treatment applications, including, but not limited to inhibiting cell migration, cell proliferation, and angiogenesis, as well as to treat cancer, pathological angiogenesis, and integrin-mediated diseases. The invention encompasses a short 14 amino acid peptide (calledRK1), purified from the venom of Buthus occitanus tunetanus, with the particular capabilities,among different other scorpion peptides, to inhibit cell proliferation, migration and angiogenesis of U87 (Glioblastoma) and IGR39 (Melanoma). Moreover, RK1 is a first peptide derived from scorpion venom exhibiting a potential anti-tumoral activity with no manifest toxicity.
(FR) L'invention concerne de nouveaux venins de scorpion et des procédés d'utilisation de ceux-ci dans diverses applications de traitement, y compris, mais sans caractère limitatif, l'inhibition de la migration cellulaire, la prolifération cellulaire et l'angiogenèse, ainsi que pour traiter le cancer, l'angiogenèse pathologique et les maladies à médiation par l'intégrine. L'invention concerne un peptide d'acide aminé court (nommé RK1), purifié à partir du venin de Buthus occitanus tunetanus, ayant des capacités particulières, parmi différents autres peptides de scorpion, pour inhiber la prolifération cellulaire, La migration et l'angiogenèse de U87 (glioblastome) et de IGR39 (mélanome). De plus, RK1 est le premier peptide dérivé à partir de venin de scorpion présentant une activité anti-tumorale potentielle sans toxicité évidente.
Latest bibliographic data on file with the International Bureau